Synthetic Amorphous Silicon Dioxide (NM-200, NM-201, NM-202, NM-203, NM-204): Characterisation and Physico-Chemical Properties

The European Commission's Joint Research Centre (JRC) provides scientific support to European Union policy including nanotechnology. Within this context, the JRC launched, in February 2011, a repository for Representative Test Materials (RTMs), based on preparatory work started in 2008. It supports both EU and international research projects, and especially the OECD Working Party on Manufactured Nanomaterials (WPMN). The WPMN leads an exploratory testing programme "Testing a Representative set of Manufactured Nanomaterials" for the development and collection of data on characterisation, toxicological and ecotoxicological properties, as well as risk assessment and safety evaluation of nanomaterials. The purpose is to understand the applicability of the OECD Test Guidelines for the testing of nanomaterials as well as end-points relevant for such materials. The Repository responds to a need for nanosafety research purposes: availability of nanomaterial from a single production batch to enhance the comparability of results between different research laboratories and projects. The availability of representative nanomaterials to the international scientific community furthermore enhances and enables development of safe materials and products. The present report presents the physico-chemical characterisation of the synthetic amorphous silicon dioxide (SiO2, SAS) from the JRC repository: NM-200, NM-201, NM-202, NM-203 and NM-204. NM-200 was selected as principal material for the OECD test programme "Testing a representative set of manufactured nanomaterials". NM-200, NM-201 and NM-204 (precipitated SAS) are produced via the precipitation process, whereas NM-202 and NM-203 (fumed or pyrogenic SAS) are produced via a high temperature process. Each of these NMs originates from one respective batch of commercially manufactured SAS. They are nanostructured, i.e. they consist of aggregated primary particles. The SAS NMs may be used as a representative material in the measurement and testing with regard to hazard identification, risk and exposure assessment studies. The results for more than 15 endpoints are addressed in the present report, including physical-chemical properties, such as size and size distribution, crystallite size and electron microscopy images. Sample and test item preparation procedures are addressed. The results are based on studies by several European laboratories participating to the NANOGENOTOX Joint Action, as well as the JRC.JRC.I.4-Nanobioscience

Titanium Dioxide, NM-100, NM-101, NM-102, NM-103, NM-104, NM-105: Characterisation and Physico-Chemical Properties

The European Commission's Joint Research Centre (JRC) provides scientific support to European Union policy including nanotechnology. Within this context, the JRC launched, in February 2011, a repository for Representative Test Materials (RTMs), based on preparatory work started in 2008. It supports both EU and international research projects, and especially the OECD Working Party on Manufactured Nanomaterials (WPMN). The WPMN leads an exploratory testing programme "Testing a Representative set of Manufactured Nanomaterials" for the development and collection of data on characterisation, toxicological and ecotoxicological properties, as well as risk assessment and safety evaluation of nanomaterials. The purpose is to understand the applicability of the OECD Test Guidelines for the testing of nanomaterials as well as end-points relevant for such materials. The Repository responds to a need for nanosafety research purposes: availability of nanomaterial from a single production batch to enhance the comparability of results between different research laboratories and projects. The availability of representative nanomaterials to the international scientific community furthermore enhances and enables development of safe materials and products. The present report presents the physico-chemical characterisation of the Titanium dioxide series from the JRC repository: NM-100, NM-101, NM-102, NM-103, NM-104 and NM-105. NM-105 was selected as principal material for the OECD test programme "Testing a representative set of manufactured nanomaterials". NM-100 is included in the series as a bulk comparator. Each of these NMs originates from one batch of commercially manufactured TiO2. The TiO2 NMs may be used as representative material in the measurement and testing with regard to hazard identification, risk and exposure assessment studies. The results for more than 15 endpoints are addressed in the present report, including physico-chemical properties, such as size and size distribution, crystallite size and electron microscopy images. Sample and test item preparation procedures are addressed. The results are based on studies by several European laboratories participating to the NANOGENOTOX Joint Action, as well as by the JRC.JRC.I.4-Nanobioscience

The elusive archaeology of Kongo urbanism: the case of Kindoki, Mbanza Nsundi (Lower Congo, DRC)

We present here results, analyses and an in-depth historical contextualisation of the fieldwork undertaken in 2012 and 2013 at the Kindoki site in the Lower Congo (DRC). This site is linked with Mbanza Nsundi, one of the Kongo Kingdom's provincial capitals, which turns out to be archaeologically 'elusive'. Pinpointing its location proved to be particularly challenging. To this end, a historically-informed excavation methodology was developed that was never implemented in Central Africa before. We combined a strategy of systematic test pits with a large-scale 50 m grid approach. A cemetery was identified on Kindoki Hill with distinct but contemporaneous quarters of a 16th-17thcenturies settlement on both sides. The cemetery itself contains mainly 18th-century burials, in all likelihood of successive Nsundi rulers. The foreign, especially Portuguese, ceramics excavated on the hilltop and the hundreds of Venetian and likely Bavarian beads found in the graves are indicative of Mbanza Nsundi's connection to trade routes linking the Atlantic coast with the Pool region. The most striking discovery is that of a previously unknown type of comb-impressed pottery, from a pit with a calibrated radiocarbon date AD 1294-1393 (2 sigma). This suggests that a settlement had been developing at Kindoki since at least the 14th century, which allows us, for the very first time, to spatially bridge Kongo history and 'prehistory'. For the entire Lower Congo region only three 14C dates posterior to AD 1000 were available before the start of the KongoKing project, twelve have been added for just Kindoki

A manually annotated Actinidia chinensis var. chinensis (kiwifruit) genome highlights the challenges associated with draft genomes and gene prediction in plants

Most published genome sequences are drafts, and most are dominated by computational gene prediction. Draft genomes typically incorporate considerable sequence data that are not assigned to chromosomes, and predicted genes without quality confidence measures. The current Actinidia chinensis (kiwifruit) 'Hongyang' draft genome has 164\ua0Mb of sequences unassigned to pseudo-chromosomes, and omissions have been identified in the gene models

ARTEFACTS: How do we want to deal with the future of our one and only planet?

The European Commission’s Science and Knowledge Service, the Joint Research Centre (JRC), decided to try working hand-in-hand with leading European science centres and museums. Behind this decision was the idea that the JRC could better support EU Institutions in engaging with the European public. The fact that European Union policies are firmly based on scientific evidence is a strong message which the JRC is uniquely able to illustrate. Such a collaboration would not only provide a platform to explain the benefits of EU policies to our daily lives but also provide an opportunity for European citizens to engage by taking a more active part in the EU policy making process for the future. A PILOT PROGRAMME To test the idea, the JRC launched an experimental programme to work with science museums: a perfect partner for three compelling reasons. Firstly, they attract a large and growing number of visitors. Leading science museums in Europe have typically 500 000 visitors per year. Furthermore, they are based in large European cities and attract local visitors as well as tourists from across Europe and beyond. The second reason for working with museums is that they have mastered the art of how to communicate key elements of sophisticated arguments across to the public and making complex topics of public interest readily accessible. That is a high-value added skill and a crucial part of the valorisation of public-funded research, never to be underestimated. Finally museums are, at present, undergoing something of a renaissance. Museums today are vibrant environments offering new techniques and technologies to both inform and entertain, and attract visitors of all demographics.JRC.H.2-Knowledge Management Methodologies, Communities and Disseminatio

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead